Chat GPT Q&A, page-175

If CPACS is proven for Bisantrene, a buyout is likely to include the following components:

1. Upfront Cash Payment:
A substantial sum reflecting the drug's current stage and potential opportunity. Bisantrene outperformed Mitoxantrone and Doxorubicin in P3 clinical trial.

2. Milestone Payments for Regional Approvals:
Payments distributed to shareholders upon regulatory approvals in various jurisdictions, ensuring compensation aligns with the drug’s progress in different markets.

3. Stock within the Purchaser:
Shares in the purchasing company, totaling a significant sum, giving shareholders a stake in the future success of the combined entity.

4. Contingent Value Rights (CVRs):
Additional payments contingent on Bisantrene achieving specific milestones, such as sales targets or further regulatory approvals, ensuring continued returns as the drug proves its value.

5. Royalty and Profit Sharing:
A 5-10% royalty on net sales for a period of 10 years, providing ongoing revenue to the original shareholders based on the drug's commercial performance.

This structured deal reduces the upfront risk for the purchaser while maximizing potential returns for the shareholders if the drug becomes highly successful. Because FTO is implicated in 25 different drug classes and 30 cancer types, and despite 40-years of research CPACS has never been achieved, we certainly realise the opportunity for Bisantrene is enormous.